This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
Dental Supplies Industry's Near-Term Outlook Looks Bright
by Sreyoshi Mukherjee
With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.
Stryker Gains From Flagship Mako and Broad Product Spectrum
by Zacks Equity Research
Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.
AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Top Analyst Reports for Intel, Adobe & Mondelez
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Adobe Systems (ADBE) and Mondelez International (MDLZ).
Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day
3 Best Dental Stocks to Keep An Eye On
by Sriparna Ghosal
Dental practice management software helps dental businesses run smoothly by ensuring safe storage and easy access of critical information.
Dentsply (XRAY) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Allscripts' (MDRX) Veradigm Collaborates With Komodo Health
by Zacks Equity Research
Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.
Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
by Zacks Equity Research
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk
by Zacks Equity Research
With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.
Here's Why You Should Add Stryker (SYK) to Your Portfolio
by Zacks Equity Research
Stryker (SYK) gains from core segments in the second quarter of 2019.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian (VAR) raises the revenue guidance for fiscal 2019.
Here's Why You Should Snap Up Baxter International (BAX) Now
by Zacks Equity Research
For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.
XRAY vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Stock Market News For Aug 5, 2019
by Zacks Equity Research
Benchmarks closed in the red on Friday to post their worst single-day decline in a month.
Stock Market News for Aug 02, 2019
by Zacks Equity Research
Benchmarks closed lower on Thursday after President Trump announced plans to impose additional tariffs on imports from China.